Cargando…

Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient

Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report a 65-year-old female with rectal adenocarcinoma who experienced severe toxicities secondary to standard dose 5-FU based chemotherapy. She was found to be heter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bukhari, Nedal, Azam, Faisal, Alfawaz, Mohammed, Zahrani, Mohammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720358/ https://www.ncbi.nlm.nih.gov/pubmed/31531249 http://dx.doi.org/10.1155/2019/5150725

Ejemplares similares

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
por: Bukhari, Nedal, et al.
Publicado: (2021)

Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report
por: Mukherji, Deborah, et al.
Publicado: (2019)

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy
por: Amstutz, Ursula, et al.
Publicado: (2008)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients
por: Savva-Bordalo, Joana, et al.
Publicado: (2010)

New advances in DPYD genotype and risk of severe toxicity under capecitabine
por: Etienne-Grimaldi, Marie-Christine, et al.
Publicado: (2017)

Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Li, Qiang, et al.
Publicado: (2014)

Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
por: Maring, J G, et al.
Publicado: (2002)

Retracted: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Research and Practice, Gastroenterology
Publicado: (2020)

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients
por: Negarandeh, Reza, et al.
Publicado: (2020)

MicroRNA-302b Enhances the Sensitivity of Hepatocellular Carcinoma Cell Lines to 5-FU via Targeting Mcl-1 and DPYD
por: Cai, Donghui, et al.
Publicado: (2015)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
por: Hishinuma, Eiji, et al.
Publicado: (2022)

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients
por: K, Ashok Varma, et al.
Publicado: (2019)

DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
por: Wigle, Theodore J., et al.
Publicado: (2019)

5-FU toxicity and nutritional deficiencies.
por: Stenram, U.
Publicado: (1993)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Prevalence of Iatrogenic Vitamin D Toxicity Among the Saudi Population of Vitamin D Users Due to Overcorrection
por: Aljehani, Faisal, et al.
Publicado: (2023)

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
por: Iachetta, Francesco, et al.
Publicado: (2019)

Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer
por: Thomas, F, et al.
Publicado: (2011)

Impact of DPYD, DPYS, and UPB1 gene variations on severe drug‐related toxicity in patients with cancer
por: Yokoi, Katsuyuki, et al.
Publicado: (2020)

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
por: Miarons, Marta, et al.
Publicado: (2023)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with DPYD Genetic Polymorphism: A Systematic Review and Meta-Analysis
por: Kim, Woorim, et al.
Publicado: (2022)

Predicting Severe Haematological Toxicity in Gastrointestinal Cancer Patients Undergoing 5-FU-Based Chemotherapy: A Bayesian Network Approach
por: Ruiz Sarrias, Oskitz, et al.
Publicado: (2023)

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach
por: Villalvazo, Priscila, et al.
Publicado: (2021)

Update on the Treatment of Metastatic Urothelial Carcinoma
por: Bukhari, Nedal, et al.
Publicado: (2018)

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene
por: García-González, Xandra, et al.
Publicado: (2018)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Effects of polymorphisms in the MTHFR gene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis
por: Liu, Dan, et al.
Publicado: (2017)

5-FU-induced cardiac toxicity - an underestimated problem in radiooncology?
por: Steger, Felix, et al.
Publicado: (2012)

Sunitinib: An Unusual Cause of Pneumothorax in a Patient With Metastatic Chromophobe Renal Cell Carcinoma
por: Bukhari, Nedal, et al.
Publicado: (2020)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_be0ft15e9imt1iv170ohs56kjb